Smoflipid Is Better Than Lipofundin for Long-Term Neurodevelopmental Outcomes in Preterm Infants

Neurodevelopmental morbidities developed more commonly in low-birth-weight premature infants. We sought to determine the effects of different lipid emulsions on the neurodevelopmental outcomes of children born prematurely. This retrospective cross-sectional study had two intervention legs, Lipofundi...

Full description

Bibliographic Details
Main Authors: I-Lun Chen, Chih-Hsing Hung, Hsin-Chun Huang
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Nutrients
Subjects:
Online Access:https://www.mdpi.com/2072-6643/13/8/2548
id doaj-6e02fa2e5d5a441a8d1e1a4e813fbe4e
record_format Article
spelling doaj-6e02fa2e5d5a441a8d1e1a4e813fbe4e2021-08-26T14:10:00ZengMDPI AGNutrients2072-66432021-07-01132548254810.3390/nu13082548Smoflipid Is Better Than Lipofundin for Long-Term Neurodevelopmental Outcomes in Preterm InfantsI-Lun Chen0Chih-Hsing Hung1Hsin-Chun Huang2Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, Kaohsiung 83301, TaiwanSchool of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Linkou 33302, TaiwanDepartment of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, Kaohsiung 83301, TaiwanNeurodevelopmental morbidities developed more commonly in low-birth-weight premature infants. We sought to determine the effects of different lipid emulsions on the neurodevelopmental outcomes of children born prematurely. This retrospective cross-sectional study had two intervention legs, Lipofundin<sup>®</sup> MCT/LCT (LIPO) versus Smoflipid<sup>®</sup> (SMOF), which are mainly differentiated by fish oil. Data of premature neonates born between 2001 and 2015 from the research database of Chang Gung Memorial Hospital with corresponding individual medical records up to July 2020 were analyzed. Long-term neurodevelopmental outcomes were defined by the international classification of disease codes −9 or −10. The prevalence of diseases was compared between LIPO and SMOF groups at five and five years old and further analyzed by stratification of 1500 g birth weight. The LIPO and SMOF groups each included 1120 neonates. Epilepsy, cerebral palsy, developmental disorder and attention-deficit hyperactivity disorder (ADHD) were significantly decreased at age two years in the SMOF group, and epilepsy, language delay (LD), ADHD and autism spectrum disorder (ASD) were significantly decreased in the SMOF group at age five years. In children with birth weight < 1500 g, ADHD was decreased in the SMOF group at ages two and five years, and ASD was decreased in the SMOF group at age five years. In children with birth weight ≥ 1500 g, epilepsy, LD and ADHD were decreased in the SMOF group at age two years. LD was decreased in the SMOF group at age five years. We conclude that lipid emulsions with fish oil improve the neurodevelopmental outcomes of children born prematurely.https://www.mdpi.com/2072-6643/13/8/2548docosahexaenoic acidnutritionfish oilparenteral nutritionlipid emulsion
collection DOAJ
language English
format Article
sources DOAJ
author I-Lun Chen
Chih-Hsing Hung
Hsin-Chun Huang
spellingShingle I-Lun Chen
Chih-Hsing Hung
Hsin-Chun Huang
Smoflipid Is Better Than Lipofundin for Long-Term Neurodevelopmental Outcomes in Preterm Infants
Nutrients
docosahexaenoic acid
nutrition
fish oil
parenteral nutrition
lipid emulsion
author_facet I-Lun Chen
Chih-Hsing Hung
Hsin-Chun Huang
author_sort I-Lun Chen
title Smoflipid Is Better Than Lipofundin for Long-Term Neurodevelopmental Outcomes in Preterm Infants
title_short Smoflipid Is Better Than Lipofundin for Long-Term Neurodevelopmental Outcomes in Preterm Infants
title_full Smoflipid Is Better Than Lipofundin for Long-Term Neurodevelopmental Outcomes in Preterm Infants
title_fullStr Smoflipid Is Better Than Lipofundin for Long-Term Neurodevelopmental Outcomes in Preterm Infants
title_full_unstemmed Smoflipid Is Better Than Lipofundin for Long-Term Neurodevelopmental Outcomes in Preterm Infants
title_sort smoflipid is better than lipofundin for long-term neurodevelopmental outcomes in preterm infants
publisher MDPI AG
series Nutrients
issn 2072-6643
publishDate 2021-07-01
description Neurodevelopmental morbidities developed more commonly in low-birth-weight premature infants. We sought to determine the effects of different lipid emulsions on the neurodevelopmental outcomes of children born prematurely. This retrospective cross-sectional study had two intervention legs, Lipofundin<sup>®</sup> MCT/LCT (LIPO) versus Smoflipid<sup>®</sup> (SMOF), which are mainly differentiated by fish oil. Data of premature neonates born between 2001 and 2015 from the research database of Chang Gung Memorial Hospital with corresponding individual medical records up to July 2020 were analyzed. Long-term neurodevelopmental outcomes were defined by the international classification of disease codes −9 or −10. The prevalence of diseases was compared between LIPO and SMOF groups at five and five years old and further analyzed by stratification of 1500 g birth weight. The LIPO and SMOF groups each included 1120 neonates. Epilepsy, cerebral palsy, developmental disorder and attention-deficit hyperactivity disorder (ADHD) were significantly decreased at age two years in the SMOF group, and epilepsy, language delay (LD), ADHD and autism spectrum disorder (ASD) were significantly decreased in the SMOF group at age five years. In children with birth weight < 1500 g, ADHD was decreased in the SMOF group at ages two and five years, and ASD was decreased in the SMOF group at age five years. In children with birth weight ≥ 1500 g, epilepsy, LD and ADHD were decreased in the SMOF group at age two years. LD was decreased in the SMOF group at age five years. We conclude that lipid emulsions with fish oil improve the neurodevelopmental outcomes of children born prematurely.
topic docosahexaenoic acid
nutrition
fish oil
parenteral nutrition
lipid emulsion
url https://www.mdpi.com/2072-6643/13/8/2548
work_keys_str_mv AT ilunchen smoflipidisbetterthanlipofundinforlongtermneurodevelopmentaloutcomesinpreterminfants
AT chihhsinghung smoflipidisbetterthanlipofundinforlongtermneurodevelopmentaloutcomesinpreterminfants
AT hsinchunhuang smoflipidisbetterthanlipofundinforlongtermneurodevelopmentaloutcomesinpreterminfants
_version_ 1721191007793446912